FY/Q4 2018 Investor Conference Call
Wednesday, February 27, 2019
Start at approx. 2:00 p.m. CET (1:00 p.m. UTC)
Investor News February 27, 2020
Fiscal 2018:
Bayer increases sales and earnings - leader in agriculture after acquisition
Group sales advance 4.5 percent (Fx & portfolio adj.) to 39.586 billion euros / EBITDA before special items increases by 2.8 percent to 9.547 billion euros, held back by currency effects of 457 million euros / Pharmaceuticals posts higher sales (Fx & portfolio adj.) and slightly lower earnings / Consumer Health: sales level with prior year (Fx & portfolio adj.), earnings decline / Crop Science reports sales gains, substantially higher earnings due to the acquisition, integration off to a strong start / Positive safety profile of glyphosate unchanged - Bayer vigorously defending itself against lawsuits/ Net income at 1.695 billion euros, impacted by one-time effects / Core earnings per share at 5.94 euros, above expectations / Net financial debt at 35.679 billion euros, significantly better than expected / Bayer confirms 2019 Group outlook and 2022 targets.
Werner Baumann | Audio recording of the presentations and discussion
You can also play the audio recording on your mobile device.
|
Wolfgang Nickl | Q4 2018 Analyst and Investor Briefing FY/Q4 2018 All in One Package for Investors and Analysts Restatement of Q2 and Q3 2018 due to PPA of Monsanto Acquisition |
